乳腺癌多基因风险评分与现场乳腺疾病后的结果相关
Jasmine Timbres1, Kelly Kohut2, Nasim Mavaddat3
1Breast Cancer Genetics, King's College London, London, United Kingdom.
概括
一个多基因风险评分 (PRS313) 可以预测未来的乳腺癌风险,在被诊断为直立管道癌 (DCIS) 或直立叶状癌 (LCIS) 的妇女. 这一分数有助于识别高风险个体,以进行个性化乳腺癌管理.
科学领域:
- 在瘤学瘤学.
- 遗传学 遗传学 是一个
- 乳腺癌研究研究 乳腺癌研究
背景情况:
- 在位管道癌 (DCIS) 和在位球状癌 (LCIS) 是具有不同进展风险的侵袭前乳腺病变.
- 无论是DCIS还是LCIS,都会增加患上逆侧乳腺癌的风险,因此需要分层分类风险.
- 识别高风险患者对于定位乳腺癌的个性化治疗和监测策略至关重要.
研究的目的:
- 评估313-SNP多基因风险评分 (PRS313) 对随后发生的乳腺癌事件的预测能力.
- 评估PRS313在DCIS或LCIS诊断后预测ipsilateral和contralateral乳腺癌发展的准确性.
主要方法:
- 来自ICICLE和GLACIER研究的数据分析,包括2,169名DCIS和185名LCIS患者.
- 使用313-SNP多基因风险评分 (PRS313) 来评估对乳腺癌的遗传倾向.
- 使用考克斯回归分析,平均随访时间为11年,以评估结果.
主要成果:
- 在DCIS (HR=1.30) 之后,在PRS313和逆侧乳腺疾病风险之间发现了显著的关联.
- 在LCIS诊断后,PRS313与ipsilateral乳腺疾病的风险增加有关 (HR=2.16).
- 这项研究表明PRS313在预测在位诊断后的各种乳腺癌事件方面的潜力.
结论:
- PRS313是一种有价值的预测器,可以预测未来乳腺癌发生的情况.
- 该得分显示了在DCIS后预测逆侧疾病和LCIS后预测逆侧疾病的特定实用性.
- PRS313可以为临床决策提供监测和降低风险的策略,以改善患者的治疗结果.
相关概念视频
01:23Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches
407
Biopharmaceutical studies constitute a vital field aiming to enhance drug delivery methods and refine therapeutic approaches, drawing upon diverse interdisciplinary knowledge. In research methodologies, the choice between controlled and non-controlled studies significantly influences the study's reliability and accuracy.
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast,...
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast,...
407
01:21Cancer Survival Analysis
648
Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...
648